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Abstract
Infection by the SARS-CoV-2 virus is mediated by the binding of its spike protein
to the membrane-bound angiotensin converting enzyme 2 (ACE2), which plays a
pivotal role in the renin-angiotensin system (RAS). The understanding of RAS
dysregulation due to this viral infection is of fundamental importance to better
understand the pathogenic mechanisms and risk factors of the coronavirus disease
COVID-19, and to design effective therapeutic strategies. To address this issue,
we built a mathematical model of RAS based on data about protein and peptide
concentrations in normotensive and hypertensive individuals. We first tested our
model on clinical data on the action of antihypertensive RAS-blocking drugs in
control individuals. Despite the simplicity of our model, it reproduces very well,
without any fitting of additional parameters, the impact of a series of drugs, i.e.
angiotensin-converting enzyme inhibitors (ACE-I), direct renin inhibitors (DRI)
and angiotensin II receptor blockers (ARB). We applied our model to analyze the
impact of SARS-CoV-2 infection on the RAS system, which we modeled through
a downregulation of ACE2 related to viral load. Moreover, we analyzed the effect
of RAS-blockers and other RAS-targeting drugs, i.e. human recombinant ACE2
(rhACE2) and angiotensin 1-7 peptide (Ang1-7), on the RAS system of
normotensive and hypertensive COVID-19 patients. We found that while ACE-I,
DRI, rhACE2 and Ang1-7 tend to improve the clinical outcomes in a
tension-dependent manner, the use of ARB appears to worsen it. The
mathematical model that we developed offers the interesting possibility of testing
in silico the RAS dysregulation upon SARS-CoV-2 infection and of predicting
how risk factors as well as different drugs, alone or in combination, impact on
RAS and disease severity.
Keywords: Mathematical modeling; Renin-Angiotensin system; SARS-CoV-2;
COVID-19; Angiotensin Converting Enzyme; RAS blockers
1 Introduction
Since December 2019, the world is facing a severe viral pandemic with millions of
infected people and hundreds of thousands of deaths [1]. The spread of the novel
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in the city
of Wuhan (China) [2, 3, 4, 5] and quickly reached hundreds of nations. SARS-CoV-
2 belongs to the coronavirus family of which some, such SARS-CoV or MERS-
CoV, have already been implicated in epidemics causing acute respiratory distress
syndromes (ARDS). The origin of the virus is still debated [6, 7, 8, 9], but the main
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hypothesis is that it originates from bat (Rhinolophus affinisor) or pangolin (Manis
javanica), as both viral genomes share high sequence identity with SARS-CoV-2.
Coronaviral genomes encode a series of structural proteins among which the spike
glycoprotein or S-protein that protrudes from the membrane surface [9]. Similarly
to what happens in the SARS-CoV virus identified in 2003, the S-protein of SARS-
CoV-2 has been shown to bind to the angiotensin converting enzyme 2 (ACE2) and
to use it as an entry receptor to the cell [9, 10, 11, 12, 13]. This protein plays a piv-
otal role in the renin-angiotensin system (RAS) signalling pathway [14] by cleaving
angiotensin I and II peptides to generate angiotensin 1–9 and the biologically active
peptide angiotensin 1–7, respectively [15, 16]. ACE2 is highly expressed in type II
alveolar cells of lung, epithelial cells of oral mucosa, colon enterocytes, myocardial
cells and kidney proximal tubule cells. Its protection role in severe ARDS is well
known [17, 18]. Indeed, it has been shown on the basis of in vitro and mouse models
that the loss of ACE2 expression causes an increased production of angiotensin II
and contributes to lung failure [18]
Already years ago, the discovery that the spike protein of SARS-CoV interferes
with the RAS system due to its binding to ACE2 [19], thus causing ACE2 downreg-
ulation, has opened interesting ways of tackling the infection through RAS mod-
ulation. Indeed, injection of a soluble form of the the recombinant human ACE2
(rhACE2, GSK2586881) in SARS-CoV infected mice appears to have a double role
[18]: slowing down the viral infection by binding to the S-protein and rescuing the
ACE2 activity, thus causing angiotensin II reduction and protecting lung from severe
failure.
rhACE2 has been tested in phase II trial for its capability of softening ARDS [20].
Although the drug is well tolerated by the patients and a significant reduction of
angiotensin II is observed, no actual improvement in the clinical distress severity
has been recorded from this pilot study [20]. Further tests are needed to understand
the biological difference between the animal model and human.
Moreover, since SARS-CoV-2 also targets ACE2 receptors to infect cells, it was
natural to suggest that rhACE2 could help in the reduction of COVID-19 severity
[21]. And indeed, it has been shown that rhACE2 inhibits SARS-CoV-2 infection
in vitro and that this inhibition depends both on the initial quantity of the virus
and on rhACE2 concentration [22]. Following these indications, a clinical trial with
exogenous submission of rhACE2 started recently [23]. A number of other clinical
trials are in progress, which target the dysregulated RAS system to restore its
functionality [24, 25, 26, 27, 28].
Hypertension and cardiovascular diseases have been shown to be risk factors upon
SARS-CoV-2 infection. This led to the question about the potential effects of the
RAS-targeting drugs used in these illnesses on COVID-19 development. There are
three categories of such drugs: angiotensin converting enzyme inhibitors (ACE-I),
angiotensin receptor blockers (ARB) and direct renin inhibitors (DRI) (Fig.1). Sev-
eral recent investigations on large cohorts of patients [29, 30, 31] seem to conclude
that there is no correlation between the intake of these drugs and substantial in-
crease of COVID-19 risk.
Despite these interesting findings, the understanding of how the coronavirus in-
fection leads to a dysregulation of the RAS system and, in severe cases, to an acute
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respiratory distress syndrome, is still far from being achieved. Gaining insights into
the perturbed RAS system would be of fundamental importance for elucidating the
pathogenic mechanisms and associated risk factors, and for designing and testing
therapeutic strategies to relieve the progression of the disease.
To advance these issues, we present here an in silico model that allowed us to study
the dynamics of the RAS system perturbed by the SARS-CoV-2 viral infection, as
well as the effect of drugs. We fitted the dynamical model on experimental data
about the concentration of proteins and peptides involved in the unperturbed RAS
system, which we collected from the literature. We extensively tested the model on
other available data and on the outcomes of therapeutic approaches that have been
designed to rescue the RAS system. Finally, we made some predictions about the
combination of SARS-CoV-2 with drugs.
2 Methods and Modeling
Modeling the renin-angiotensin system
The RAS system has been widely studied [32, 33, 34]. It plays a key role in the
regulation of a large series of physiological systems among which the renal, lung
and cardiovascular systems. Consequently, its dysregulation is related to multiple
pathological conditions such as hypertension and ARDS, just to mention some of
them [35, 36, 37, 38, 39].
There are two different types of RAS: the circulating RAS that is localized in the
plasma and is involved in the regulation of the cardiovascular system, and the tissue-
localized systems that act intracellularly or interstitially within different organs in
association with the systemic RAS or independently of it. Here we focus on the
local RAS within the pulmonary circulation and model its network of biochemical
reactions schematically depicted in Fig. 1.
When the blood pressure decreases, the juxtaglomerular kidney cells that sense
changes in renal perfusion pressure secret an aspartic protease protein called renin
(RE, EC 3.4.23.15). The activity of this enzyme, called plasma renin activity (PRA),
is the common measure used in clinical practice to set up diagnosis and treatment
design of essential hypertension.
The dynamics of the renin concentration can be modeled as:
d[RE]
dt
= β − Log 2
hre
[RE] (1)
where hre is renin’s half-life and β its production rate. The latter is not constant
but depends on other elements of the RAS system which we will discuss later in
the section. The role of renin is to cleave the N-terminus of a protein from the ser-
ine protease inhibitor family called angiotensinogen (AGT) to form the decapeptide
hormone angiotensin I (AngI). Assuming non-linear Michaelis-Menten kinetics, the
dynamics of the angiotensinogen can be written as:
d[AGT]
dt
= kagt − krecat
[RE][AGT]
[AGT] +KreM
− Log 2
hagt
[AGT] (2)
where kagt is AGT’s production rate, hagt its half-life, k
re
cat the turnover number of
the enzymatic reaction and KreM the Michaelis constant. Although the substrate
Pucci et al. Page 4 of 22
Ang IV
Ang 1-7
Ang IIAng I
AGT
AT1R -
AngII
ACE
ACE2
CHYM
NEP
AT2R- 
AngII
AT1R
AT2R
ARB
DRI 
ACE-I
RE
PRA
MAS -
Ang 1-7
MAS
SARS-
CoV-2
Figure 1 Schematic representation of the RAS system. In the unperturbed system, soluble
proteins that are explicitly considered in the model are in grey blue, the peptides in light blue and
the peptide-bound membrane proteins in mid blue. The activities and enzymes considered only
through reaction rates are in green. The feedback loop is indicated in blue. In the perturbed
system, the drugs are in orange and SARS-CoV-2 in dark red.
concentration [AGT] ∼ KreM and thus influences the reaction rate, the AGT concen-
tration is much larger than the RE concentration which, as a consequence, impacts
more on the RAS regulation. Eq. (2) can thus be linearly approximated as:
d[AGT]
dt
= kagt − cre[RE]− Log 2
hagt
[AGT] (3)
where the reaction rate cre relates the renin concentration to its activity.
The AngI peptide is further cleaved by different enzymes:
• The angiotensin-converting enzyme (ACE, EC3.4.15.1), a zinc metallopro-
teinase located mainly in the capillaries of the lungs and in the endothelial
cells. It catalyzes the transformation of AngI into the octapeptide angiotensin
II (AngII).
• Chymase (CHY, EC 3.4.21.39), a serine protease that is mainly localized in
blood vessels and heart. It also catalyzes the transformation of AngI into
AngII.
• Neprilysin (NEP, EC3.4.24.11), another zinc metalloproteinase that is ex-
pressed in a wide variety of tissues. It catalyzes the transformation of AngI
into the heptapeptide hormone angiotensin-(1-7) (Ang1-7).
The dynamics of AngI can thus be described as:
d[AngI]
dt
= cre[RE]− (cace + cchy + cnep) [AngI]− Log 2
hangI
[AngI] (4)
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where cace, cchy and cnep are the reaction rates associated with the corresponding
enzymatic reactions. To get this relation, we started from the non-linear Michaelis-
Menten kinetic term, which reads for ACE: [ACE][AngI]/([AngI] +KaceM ). As the sub-
strate concentration [AngI] is here much lower than the Michaelis constant of the
reaction ([AngI] << KaceM ), we dropped it from the denominator and consider fixed
the equilibrium concentrations of the ACE enzyme, so that the reaction term becomes
linear in the concentration of the AngI substrate. We made the same approximation
for the reactions involving CHY and NEP and for all other reactions described below.
The role of AngII in the RAS system is central since it has a vasoconstriction
effect, enhances blood pressure, and triggers inflammatory processes and fibrosis.
In lung, the capillary blood vessels are among the sites that have the highest ACE
expression and production of AngII. Its dysregulation has frequently been related
to a wide series of chronic and acute diseases such as pulmonary fibrosis and ARDS.
AngII effects are mediated by two G-protein coupled receptors (GPCR) called
angiotensin II type 1 (AT1R) and type 2 (AT2R). In addition, it can be cleaved by
different enzymes. For example, aminopeptidase A (APA, EC 3.4. 11.7) generates
other peptides such as angiotensin III (AngIII) that is further cleaved to AngIV.
We skipped in our model all details about the enzymatic reactions AngII-AngIII-
AngIV and kept only a single equation for their transformation. Moreover, the ACE2
enzyme generates Ang1-7 peptides. The dynamics of AngII and AngIV can thus be
written as:
d[AngII]
dt
= (cace + cchy) [AngI]
− (cace2 + cangIV + cat1r + cat2r) [AngII]− Log 2
hangII
[AngII](5)
d[AngIV]
dt
= cangIV [AngII]− Log 2
hangIV
[AngIV] (6)
where hangII and hangIV are the half-lives of the corresponding peptides and cace2,
cangIV , cat1r and cat2r the rates associated to the respective enzymatic reactions.
The dynamics of the peptide-bound form of the GPCRs are expressed as:
d[AT1R-AngII]
dt
= cat1r[AngII]− Log 2
hat1r
[AT1R-AngII] (7)
d[AT2R-AngII]
dt
= cat2r[AngII]− Log 2
hat2r
[AT2R-AngII] (8)
where [AT1R-AngII] and [AT1R-AngII] are the concentrations of the bound forms
of the receptors, and hat1r and hat2r their half-lives.
Until now, we have modeled the ACE/AngII/AT1R regulatory axis of the RAS
system. Since the last two decades, it became clear that there is another RAS axis
that acts as a counterregulator of the first axis [40]. The key role of this second
axis is played by the Ang1-7 peptide that is mainly produced from AngII by the
ACE2 enzyme and binds to the transmembrane GPCR called MAS. However, Ang1-7
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can be also obtained as an enzymatic product from AngI via the catalytic activity
of NEP and, to a lesser extent, from Ang1-9 via ACE and NEP. We overlooked the
Ang1-9-related enzymatic reactions in our model, as they contribute less to Ang1-7
formation [33, 34]. The dynamical equations for the Ang1-7 peptide and the MAS-
bound receptor are as follows:
d[Ang1-7]
dt
= cnep[AngI] + cace2[AngII]− cmas[Ang1-7]− Log 2
hang1−7
[Ang1-7] (9)
d[MAS-Ang1-7]
dt
= cmas[Ang1-7]− Log 2
hmas
[MAS-Ang1-7] (10)
Let us now go back to Eq. (1) in which we simply expressed the renin production
as a baseline term β. To describe the autoregulatory nature of the RAS system,
this term has to depend on the production of other species, thus introducing a
feedback regulation. It is known that this feedback depends on AT1R bound to
AngII. Following other models [41, 42], we expressed β as:
β = β0 +
((
[AT1R-AngII]N0
[AT1R-AngII]
)δ
− 1
)
(11)
where β0 is a constant parameter to be identified and [AT1R-AngII]
N
0 the equilibrium
concentration for healthy normotensive humans. δ is a positive number that we fixed
to 0.8 [41].
Monitoring the blood pressure
Blood pressure is well known to be increased by the concentration of AngII bound
to AT1R. It has also been described to be decreased by the concentration of MAS
bound to Ang1-7 and of AT2R bound to AngII, but the precise mechanism is not
yet known [43, 44, 45]. Therefore, we did not introduce in our model a feedback
between these concentrations and renin production, as we did for AT1R-AngII and
modeled the blood pressure (DBP) simply from the AT1R-AngII concentration:
DBP = P0 + P1[AT1R-AngII] (12)
We chose to fix the two parameters P0 and P1 to mimic the diastolic blood pressure
(DBP) rather than the systolic one. We thus fixed DBP equal to 80 mmHg for
normotensive humans and to 110 mmHg for hypertensive humans. Hence, P0 +
P1[AT1R-AngII]
N
0 = 80 mmHg and P0 +P1[AT1R-AngII]
H
0 = 110 mmHg, where the
N and H superscripts denote the concentration in normotensive and hypertensive
humans and the 0 subscript, equilibrium concentrations.
Modeling the effect of RAS-targeting drugs
Since dysregulated RAS and in particular elevated levels of AngII are related to
essential hypertension, a wide range of RAS-targeting drugs have been developed in
the last fourty years [46]. They can be classified in three different categories based
on their pharamacological target [47]:
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• Angiotensin-converting enzyme inhibitors (ACE-I) that bind to ACE and thus
inhibit the formation of angiotensin II and the associated vasoconstriction
and inflammatory cascades. Examples of this type of drugs are enalapril,
lisinopril and captopril.
• Angiotensin receptor blockers (ARB) that block the binding of AngII to AT1R
and thus act in antagonism with AngII. Examples are candesartan, losartan
and valsartan.
• Direct renin inhibitors (DRI) that act on renin and thus inihibit the conver-
sion of AGT to AngI. Examples are aliskiren, enalkiren and remikiren.
We modeled the action of these three types of drugs by modifying the reaction
rates associated to their targets as:
cace −→ cace × (1− γACE-I)
cat1r −→ cat1r × (1− γARB)
cre −→ cre × (1− γDRI) (13)
where γACE-I, γARB and γDRI are parameters describing the drug activity.
Modeling COVID-19 infection
Since ACE2 is the entry point of SARS-CoV-2 [19], it is downregulated upon in-
fection, and this impacts substantially on the local and systemic RAS systems. In
order to model the downregulation effect due to the virus, we modified the ACE2
rate with the function γCoV as:
cace2 −→ cace2 × (1− γCoV(Ct)) (14)
This function has been chosen to be a sigmoid function of the cycle threshold
value Ct, which is inversely related to the viral load [48], as:
γCoV =
1
1 + eaCt−b
(15)
It is represented in Fig. 3.a. The inflection point of the sigmoid, corresponding to
mild disease, has been chosen to be at a Ct value of 31.5 [49]. The values of Ct = 27.6
and 23.8 correspond to moderate and severe diseases, respectively, and Ct > 40 to
undetected viral infection. We thus imposed γCoV > 0.99 for Ct > 40. Using these
relations, we identified the values of the parameters a and b of Eq. (15). They are
reported in Table 2.
Monitoring the acute respiratory distress syndrome and its severity
To model how the lungs of the infected patients evolve in response to the modula-
tion of the RAS system, we introduced a phenomenological relation to estimate the
PaO2/FiO2 ratio, defined as the ratio between the partial pressure of arterial oxy-
gen (PaO2) and the fraction of inspired oxygen (FiO2). This quantity plays a key
role in the assessment of ARDS patients [50, 51]. The normal range of PaO2/FiO2
is between 400 and 500 mmHg. Mild and moderate ARDS are characterized by
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PaO2/FiO2 values in the range [200–300] mmHg and [100-200] mmHg, respec-
tively. ARDS is severe for values below 100 mmHg.
We predicted the PaO2/FiO2 ratio as a function of the AngII and Ang1-7 con-
centrations:
PaO2/FiO2 = A0 +A1
(
− [AngII]
[AngII]0
+
[Ang1-7]
[Ang1-7]0
)
(16)
where A0 and A1 are two parameters that we identified from our model by com-
paring the baseline RAS with the same system in which ACE2 is knocked out. In
the former we fixed PaO2/FiO2= 450 mmHg and in the latter PaO2/FiO2= 50
mmHg.
Solving the RAS model
The mathematical model of the RAS system described in Eqs (1)-(11) is a system
of ordinary differential equations (ODEs), which are linear except for the feedback
loop of Eq. (11). We collected from the literature the values of the equilibrium
concentrations of all proteins and peptides for both normotensive and hypertensive
humans (Table 1), except renin and MAS bound to Ang1-7. From these values, we
fixed the parameters that appear in the phenomenological relations (12) and (16)
for DBP and PaO2/FiO2 (Table 2).
We also got the values of the half-life of all proteins and peptides but MAS; we
assumed the latter to be equal to that of the other membrane receptors (Table 2).
Moreover, we estimated the value of reaction rate cre from [52, 53].
Using these concentration and parameter values, we solved the system of nine
ODEs (Eqs (1) and (3)-(10)) at the stationary state to identify the unknown pa-
rameters and concentrations. However, these equations have 12 unknowns: kagt, β0,
cace, cace2, cangIV , cat1r, cat2r, cmas, cchy, cnep, [RE]0 and [MAS-Ang1-7]0. We had
thus to assume three additional relations to be able to solve the system. These are:
cmas = cat2r (17)
cchy = 0 (18)
cnep = 0 (19)
Since no quantitative data related to the MAS receptor can be found in the literature,
we hypothesized the first relation assuming MAS and AT2R to be equally expressed
and the affinity of Ang1-7 for MAS to be similar to the affinity of AngII for AT2R
[44]. Moreover, we assumed cchy = 0 and cnep = 0, but discussed the effect of
non-vanishing values in the Discussion section.
Imposing these three additional relations, we solved the system of 9 ODEs (1)-
(11) at the stationary state. The values obtained for [RE]0 and [MAS-Ang1-7]0, kagt,
β0, cace, cace2, cangIV , cat1r and cat2r for normotensive and hypertensive humans
are given in Table 1.
Stability of the RAS model
The system of nine ODEs (Eqs (1) and (3)-(10)) can be summarized in the form:
dx(t)
dt
= f(x(t), θ) (20)
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Parameter Unit Normotensive Hypertensive Reference
[AGT]0 fmol/ml 6 ×105 6 ×105 [54]
[AngI]0 fmol/ml 70 110 [55, 56]
[AngII]0 fmol/ml 28 156 [55, 56]
[Ang1-7]0 fmol/ml 36 92 [55, 56, 57]
[AngIV]0 fmol/ml 1 1 [58]
[AT1R-AngII]0 fmol/ml 15 85 [41]
[AT2R-AngII]0 fmol/ml 5 27 [41]
[RE]0 fmol/ml 9.43 25.25 Solved
[MAS-Ang1-7]0 fmol/ml 6.43 15.92 Solved
kagt fmol/(ml min) 881.82 1198.22 Solved
β0 fmol/(ml min) 0.54 2.21 Solved
cace 1/min 1.31 3.21 Solved
cace2 1/min 1.80 0.82 Solved
cangIV 1/min 0.05 0.01 Solved
cat1r 1/min 0.03 0.03 Solved
cat2r 1/min 0.01 0.01 Solved
Table 1 Equilibrium concentrations of the species involved in the RAS system as well as production
and reaction rates parameters for normotensive and hypertensive humans. Solved means solved from
the model.
Parameter Unit Values Reference
hagt min 600 [59]
hang1−7 min 0.5 [59]
hangI min 0.5 [59]
hangII min 0.5 [59]
hangIV min 0.5 [59]
hat1r min 12 [59]
hat2r min 12 [59]
hre min 12 [59]
hmas min 12 -
cre 1/min 20 [52, 53]
A0 mmHg 450 Fitted
A1 mmHg 267 Fitted
P0 mmHg 73.6 Fitted
P1 mmHg ml/fmol 0.43 Fitted
a - 0.53 Fitted
b - 16.7 Fitted
Table 2 Half-lives of the different species involved in the RAS system and other parameters of the
model.
where x(t) is the vector containing the nine state variables, i.e. the concentrations
of all proteins and peptides at time t, θ is the vector with all the production, kinetic
and half-live parameters, and f represents the vector that corresponds to the right-
hand sides of Eqs (1) and (3)-(10). In order to analyze the stability of the two steady
states xN0 and x
H
0 for normotensive and hypertensive individuals, respectively, we
computed the eigenvalues of the Jacobian matrix:
J(x0) =
∂f(x, θ)
∂x
∣∣∣
x=x0
(21)
where x0 stands for either x
N
0 or x
H
0 .
In both the normotensive and hypertensive cases, seven strictly negative real
values were obtained, together with two complex conjugate eigenvalues with strictly
negative real parts. Both steady-states xN0 and x
H
0 are therefore stable. The nonzero
imaginary parts of the two complex conjugate eigenvalues are responsible of some
damped oscillations in transient responses to parameter changes, but the overshoots
are quite limited. It is interesting to note that the imaginary part is more than three
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times lower in the hypertensive case, hence leading to more damped responses in
comparison with the normotensive case.
To quantify the state variable transients and the aforementioned overshoots, we
simulated step responses corresponding to 10% increase in the normal baseline for
renin production β0. We observe some damped oscillations during the transient
phase of the normotensive case, with very limited overshoots, e.g. 1.3% for RE
concentration. In the hypertensive case, the imaginary part of the complex conjugate
eigenvalues is sufficiently low so that the overshoots become almost undetectable
(0.025%).
3 Results
The main objective of this paper is to investigate how RAS-targeting drugs, SARS-
CoV-2 infection and their combination impact on the RAS system of both nor-
motensive and hypertensive individuals. Before introducing ACE2 downregulation
due to viral infection, we started checking the robustness and predictive power of
our model by analyzing the effects on RAS of the three types of antihypertensive
drugs ACE-I, ARB and DRI described in section 2, and comparing model simula-
tions with clinical data from patients.
Modeling the impact of antihypertensive RAS-blocker drugs on RAS
The effect of the ACE-I type drug enalapril on plasma ACE activity and on plasma
levels of AngI and AngII has been measured in normotensive individuals, after they
took a single oral dose of 20 mg [60]. To compare this data with the results of our
model, we fitted the γACE-I function introduced in Eq. (13) to follow the measured
values of ACE activity during treatment divided by the activity before treatment,
which was measured through an antibody-trapping assay. The dynamical response
to this inhibiting drug is represented in Figs 2.a-b, where the time-dependent values
of AngI and AngII concentrations, normalized by their concentration at time 0, is
shown both for our prediction model and experimental data. We observed a very
good agreement between the two curves, without any further fitting of parameters.
The good correspondence between prediction and experiment is also visible from the
root mean square deviation between experimental and predicted values at different
times after drug administration, shown in Table 3.
Our model is thus able to capture the known dynamics upon ACE inhibition con-
sisting of an increase of AngI level and a decrease of AngII level, which has the
effect of lowering the concentration of AngII bound to AT1R and thus also the blood
pressure (Eq. (12)).
To study the effect of ARB antihypertensive drugs, we considered data from [61]
where the effects of different types of AT1R blocking molecules on plasma levels
of AngII were measured in normotensive individuals. More precisely, the individu-
als were given a single dose of losartan 50 mg, valsartan 80 mg or irbesartan 150
mg. First we fitted the function γARB defined in Eq. (13) onto the in vitro ability
of the drug to induce the AngII receptor blockade measured by an AT1R radiore-
ceptor binding assay [61]. Our model was then used to predict the time-dependent
AngI level normalized by its concentration before drug intake. The results evaluated
through the root mean square deviation between experimental and predicted values
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• Angiotensin receptor blockers (ARB) that block the binding of AngII to AT1R
and thus act in antagonism with AngII. Examples are candesartan, losartan
and valsartan.
• Direct renin inhibitors (DRI) that act on renin and thus inihibit the conver-
sion of AGT to AngI. Examples are aliskiren, enalkiren and remikiren.
We modeled the action of these three types of drugs by modifying the reaction
rates associated to their targets as:
cace  ! cace ⇥ (1   ACE-I)
cat1r  ! cat1r ⇥ (1   ARB)
cre  ! cre ⇥ (1   DRI) (13)
where  ACE-I,  ARB and  DRI are parameters describing the drug activity.
Modeling CoViD-19 infection
Since ACE2 is the entry point of SARS-CoV-2 [19], it is downregulated upon in-
fection, and this impacts substantially on the local and systemic RAS systems. In
order to model the downregulation e↵ect due to the virus, we modified the ACE2
rate with the function  CoV as:
cace2  ! cace2 ⇥ (1   CoV(Ct)) (14)
This function depends on the virus cycle threshold value Ct, which is inversely
related to the viral load [69].
Monitoring the acute respiratory distress syndrome and its severity
To model how the lungs of the infected patients evolve in response to the modulation
of the RAS system, we introduced a phenomenological relation to estimate the
PaO2/FiO2 ratio, defined as the ratio between the partial pressure of arterial
oxygen (PaO2) and the fraction of inspired oxygen. This quantity plays a key role
in the assessment of ARDS patients [34, 35]. The normal range of PaO2/FiO2
is between 400 and 500 mmHg. Mild and moderate ARDS are characterized by
PaO2/FiO2 values in the range [200–300] mmHg and [100-200] mmHg, respectively.
ARDS is severe for values below 100 mmHg.
We predicted the PaO2/FiO2 ratio as a function of the AngII and Ang1-7 con-
centrations:
PaO2/FiO2 = A0 +A1
✓
  [AngII]
[AngII]0
+
[Ang1-7]
[Ang1-7]0
◆
(15)
where A0 and A1 are two parameters that we identified from our model by com-
paring the baseline RAS with the same system in which ACE2 is knocked out. In
the former we fixed PaO2/FiO2= 450 mmHg and in the latter PaO2/FiO2= 50
mmHg.
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• Angiotensin receptor blockers (ARB) that block the binding of AngII to AT1R
and thus act in antagonism with AngII. Examples are candesartan, losartan
and valsartan.
• Direct renin inhibitors (DRI) that act on renin and thus inihibit the conver-
sion of AGT to AngI. Examples are aliskiren, enalkiren and remikiren.
We modeled the action of these three types of drugs by modifying the reaction
rates associated to their targets as:
cace  ! cace ⇥ (1   ACE-I)
cat1r  ! cat1r ⇥ (1   ARB)
cre  ! cre ⇥ (1   DRI) (13)
where  ACE-I,  ARB and  DRI are parameters describing the drug activity.
Modeling CoViD-19 infection
Since ACE2 is the entry point of SARS-CoV-2 [19], it is downregulated upon in-
fection, and this impacts substantially on the local and systemic RAS systems. In
order to model the downregulation e↵ect due to the virus, we modified the ACE2
rate with the function  CoV as:
cace2  ! cace2 ⇥ (1   CoV(Ct)) (14)
This function depends on the virus cycle threshold value Ct, which is inversely
related to the viral load [69].
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Figure 2 Dynamical response of RAS to ACE-I administration. Comparison between the
computational prediction (green) and the experimental data (brown) of the normalized AngI (a)
and AngII (b) as a function of time (in hours) after the intake of a single dose. Continuum lines
are obtained through data interpolation. (c) Pr dicted DBP as a fu ction of γACE-I values (green
line) and DBP measurements averaged over ore than ten ACE-I types as a function of the
dosage divided by the maximal dosage (brown points). (d) Predicted effect of the combination of
ACE-I and ARB on the DPB values.
of AngI/AngI0 at different tim points aft r drug ad inistration are reported in
Table 3. We clearly see that our model predicts very well the response of the RAS
system to ARBs.
We also studied the effect of DRI-type drugs using data about the impact of oral
administration of aliskiren at different doses to normot n i e individuals on PRA
activity and on RE, AngI and AngII concentrations [62]. We used the PRA activity
data to fit the γDRI function introduced in Eq. (13) and computed from our model
the normalized AngI and AngII levels as a function of time. We then compared our
results with the experimental concentrations and fou d a good agreement as shown
in Table 3.
The root mean square deviation between predicted and experimental values of
normalized AngI and AngII levels, averaged over all tested drugs, is equal to 0.57
and 0.18, respectively (Table 3). There is thus an excellent agreement between
experiments and predictions.
Let us remember that all the data reported until now have been obtained with
single doses of RAS-targeting drugs. However, in hypertensive patients on long-term
treatment, the expression of some of the enzymes involved in the RAS system could
be up- or down-regulated. We will come back to this point in the Discussion section.
Finally, we also compared the effect of the intake of ACE-I and ARB drugs on
blood pressure, as predicted from our model and measured from large cohorts of
patients [63, 64]. We first analyzed the response to ACE-I drugs alone. We plotted
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Drugs Class Dose [AngI](t)/[AngI]0 [AngII](t)/[AngII]0 Np Ref.
σ(exp-pred) σ(exp-pred)
Enalapril ACE-I 20mg 1.31 0.09 5 [60]
Losartan ARB 50mg 0.61 - 3 [61]
Valsartan ARB 850mg 0.83 - 3 [61]
Irbesartan ARB 150mg 0.97 - 3 [61]
Aliskiren DRI 40mg 0.13 0.14 6 [62]
Aliskiren DRI 80mg 0.15 0.16 6 [62]
Aliskiren DRI 160mg 0.26 0.20 6 [62]
Aliskiren DRI 640mg 0.29 0.29 6 [62]
Mean 0.57 0.18
Table 3 Comparison between model predictions and experimental values of AngI and AngII levels
normalized by their value before the intake of the drugs. σ is the root mean square deviation between
experimental and predicted values computed on the different time points. Np is the number of time
points.
the predicted values of DBP as a function of γACE-I values in Fig 2.c, as well
as the DBP measurements averaged over a set of more than 10 types of ACE-I
drugs as a function of the normalized dosage obtained in [63]. For this purpose, we
fixed γACE-I = 0.5 at the maximal dosage and considered a linear relation between
γACE-I and dosage. Note that we could have introduced additional parameters to
define a non-linear relationship between these two quantities and thus obtain a
better fit. Despite these simplifications, the curve follows the experimental data
reasonably well.
We also studied the effect of joint intake of the two drugs ARB and ACE-I on the
blood pressure. We plotted the predicted DBP as a function of the functions γACE-I
and γARB in Fig. 2.d. We found that the combination of ACE-I and ARB reduces
the DBP by 4 mmHg when compared with ARB monotherapy, and by 12 mmHg in
comparison with ACE-I monotherapy. These predictions have to be compared with
clinical values of 3 mmHg for joint therapy compared to both monotherapies [64].
Thus, also in this case, our model reproduces very well the clinical data; note that
to have even better data reproduction, the γARB value at the maximum dose should
probably be fixed slightly lower than the corresponding γACE-I value.
RAS and its inhibition in COVID-19
ACE2 is known to be the cellular receptor of the spike glycoprotein S1 of SARS-
CoV-2 [9, 10, 11, 12, 13], and to trigger the entry of the virus into the host cell. It
is expressed in a variety of tissues [65, 66, 67], but mainly in the gastrointestinal
tract and in the alveolar epithelial cells of the lung.
Here we used our model to predict how the RAS system gets perturbed by the
SARS-CoV-2 virus. Results of the simulations for AngII and Ang1-7 concentrations
and for the physiological PaO2/FiO2 value are shown in Fig.3.b-d and in Table 4.
First, we observe that the AngII level increases with increasing viral load. The
increase is much stronger for hypertensive than for normotensive patients. The
predicted increase is of about 18% between mild and severe COVID-19 patients
(Table 4). This prediction is in good agreement with [68] where an increase of
about 15% was found, but differs from [69] where a more substantial increase was
obtained on very limited number of 12 patients.
We also observe that our model predicts an extremely severe reduction of the level
of Ang1-7, due to the downregulation of ACE2, which is identical for hypertensive
and normotensive patients.
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Uninfected Mild Moderate Severe
Ct 40.0 31.5 27.6 23.8
Normotensive
[AngII] (fmol/ml) 28 32 36 38
[Ang1-7] (fmol/ml) 36 21 5 1
PaO2/FiO2 (mmHg) 450 300 145 98
DBP (mmHg) 80 81 82 82
Hypertensive
[AngII] (fmol/ml) 156 186 221 231
[Ang1-7] (fmol/ml) 92 55 15 2
PaO2/FiO2 (mmHg) 450 292 115 60
DBP (mmHg) 110 117 125 128
Table 4 Prediction of biochemical and clinical features of SARS-CoV-2 infected patients.
The picture that comes out is that the RAS system gets unbalanced, with the
harmful AngII axis upregulated and the counteracting Ang1-7 axis severely down-
regulated. This imbalance can be related to multiple clinical manifestations of the
disease. More precisely, hyperinflammation occurs upon increase in [AngII], which
enhances plasma proinflammatory cytokine levels (in particular IL-6) [70, 71]. In
addition, thrombotic events are observed, since AngII promotes the expression of
plasminogen activator inhibitor (PAI)-1 and tissue-factors (TFs) [72, 73]. Ang1-7,
which normally counteracts these various effects [40], is downregulated by the SARS-
CoV-2 infection, with the consequence that these clinical manifestations become
more and more severe with COVID-19 disease development.
Moreover, our model predicts severe ARDS with PaO2/FiO2 < 100 mmHg for
normotensive and hypertensive patients having Ct values smaller than 24.1 and 27.0,
respectively. It predicts moderate ARDS characterized by a PaO2/FiO2 ratio in
the 100-200 mmHg range for normotensive and hypertensive patients having 24.1 <
Ct < 29.3 and 27.0 < Ct < 29.7, respectively, and mild ARDS with PaO2/FiO2
between 200 and 300 mmHg for normotensive and hypertensive patients that have
29.3 < Ct < 31.4 and 29.7 < Ct < 31.6.
Our computational approach suggests a mild relation between hypertension and
ARDS severity as a consequence of the viral infection. Indeed, the mean value of the
PaO2/FiO2 ratio over the whole Ct range is about 20 mmHg lower for hypertensive
than for normotensive patients. Indeed, the large difference in AngII levels between
normo- and hypertensive individuals is partially compensated by the absence of
difference in Ang1-7 levels.
Impact of RAS-modulating drugs on COVID-19 severity
We analyzed the impact of different drugs in normotensive and hypertensive patients
who are affected by SARS-CoV-2 infection. More precisely, we considered RAS-
blocking drugs used as therapies in essential hypertension as well as drugs such as
rhACE2 and Ang1-7 which are under clinical trials in the context of COVID-19.
• Antihypertensive RAS-blocking drugs. We combined the effect of each of the
three RAS-blocking drugs ACE-I, ARB and DRI modeled by the enzyme-inhibiting
γ functions introduced in Eq. (13), with the ACE2-inhibiting Ct-dependent γ function
defined in Eq. (14) which mimics SARS-CoV-2 infection. The PaO2/FiO2 values
predicted by the model are shown in Fig. 4.
According to our model, the effect of ACE-I and DRI drugs are beneficial against
ARDS, especially for hypertensive patients. In contrast, ARB drugs are predicted
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Monitoring the acute respiratory distress syndrome and its severity
To model how the lungs of the infected patients evolve in response to the modulation of the
RAS system, we introduced a phenomenological relation to estimate the PaO2/FiO2 ratio,
defined as the ratio between the partial pressure of arterial oxygen (PaO2) and the fraction of
inspired oxygen. This quantity plays a key role in the assessment of ARDS patients [34, 35].
The normal range of PaO2/FiO2 is between 400 and 500 mmHg. Mild and moderate ARDS
are characterized by PaO2/FiO2 values in the range [200–300] mmHg and [100-200] mmHg,
respectively. ARDS is severe for values below 100 mmHg.
We predicted the PaO2/FiO2 ratio as a function of the AngII and Ang1-7 concentrations:
PaO2/FiO2 = A0 +A1
✓
  [AngII]
[AngII]0
+
[Ang1-7]
[Ang1-7]0
◆
(15)
where A0 and A1 are two parameters that we identified from our model by comparing the
baseline RAS with the same system in which ACE2 is knocked out. In the former we fixed
PaO2/FiO2= 450 mmHg and in the latter PaO2/FiO2= 50 mmHg.
Solving the RAS model
xx should this part not be in the Results section? With the paragraph of Philippe ? xx
The mathematical model of the RAS system described in Eqs (1)-(11) is a system of
ordinary di↵erential equations (ODEs), which are linear except for the feedback loop of Eq.
(11). We collected from the literature the values of the equilibrium concentrations of all
proteins and peptides for both normotensive and hypertensive humans (Table 1), except
renin and MAS bound to Ang1-7. From these values, we fixed the parameters that appear in
the phenomenological relations (12) and (15) for DBP and PaO2/FiO2 (2).
We also got the values of the half-life of all proteins and peptides but MAS; we assumed the
latter to be equal to that of the other membrane receptors (Table 2). Moreover, we estimated
the value of reaction rate cre from [32, 33].
Using these concentration and parameter values, we solved the system of 9 ODEs (1)-(11)
at the stationary state to identify the unknown parameters and concentrations. However,
these equations have 12 unknowns: kagt,  0, cace, cace2, cangIV , cat1r, cat2r, cmas, cchy, cnep,
[RE] and [MAS-Ang1-7]. We had thus to assume three additional relations to be able to solve
the system. These are:
cmas = cat2r (16)
cchy = 0 (17)
cnep = 0 (18)
Since no quantitative data related to the MAS receptor can be found in the literature, we
hypothesized the first relation assuming MAS and AT2R to be equally expressed and the a nity
of Ang1-7 for MAS to be similar to the a nity of AngII for AT2R [46]. Moreover, we assumed
cchy = 0 and cnep = 0, but carefully discussed the e↵ect of non-vanishing values in the
Discussion section.
Imposing these three additional relations, we solved the system of 9 ODEs (1)-(11) at the
stationary state. The values obtained for [RE] and [MAS-Ang1-7], kagt,  0, cace, cace2, cangIV ,
cat1r and cat2r for normotensive and hypertensive humans are given in Table 1.
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Figure 3 Simulated response of the RAS system to viral infection. (a) γCoV function used to
model the effect of the infection as a function of Ct, the cycle threshold of the virus. (b)-(d)
Predictions obtained from our model f r the n rmalized levels of AngII and Ang1-7, and for the
physiological PaO2/FiO2 value as a functi n of Ct, for normotensive (blue) and hypertensive
(red) individuals.
to increase the severity of th disease, and this effect is more pronounced for nor-
motensive patients.
The results on ACE inhibitors are in agreement with clinical data, which indicate
that the use of these drugs is associated with better surviv l among COVID-19
patients [31, 74]. Indeed, out of the ensemble of patients analyzed [31], only 3%
of the non-surviving ones were taking ACE-I while this percentage rises to 9% for
the surviving ones. Moreover, i a me a-analysis [74], hypert nsive patients taking
ACE-I were associated with a reduced mortality of 35% with respect to patients no
taking them. In another clinical analysis [75], a 40% lower risk of hospitalization
was observed for older people who were under ACE-I treatment.
There are currently no data to validate or invalidate our prediction according
to which the attenuation of the severity of the disease due to ACE-I is stronger
in hypertensive than in normotensive patients. Also, no data about the positive
impact of DRI drugs similar to ACE-I are available in the literature. It would be
extremely valuable to test our predictions on the basis of clinical data.
For ARB drugs, we predicted the opposite tendency: taking these drugs worsens
the disease and this effect is stronger for normotensive compared to hypertensive
patients. Here the agreement with clinical data is less clear. Some data seem to
support the behavior that we observe [31, 75], even though the percentage of pa-
tients assuming ARB drugs in non-surviving patients is higher but not statistically
significantly higher than in surviving patients. In yet other analysis, no change in
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the risk of hospitalization [75] or in the mortality [74, 76] is observed compared with
the control group. More data should be collected to settle this issue.
In order to have a quantitative view of the predicted trends, we computed the
values of the concentration of RAS peptides, the PaO2/FiO2 value and the DPB for
patients with a moderate COVID-19 infection and the evolution of these quantities
after drug administration. The results are shown in Table 5.
Administration of ACE-I drugs, modelled by γACE−I = 0.5, increases the
PaO2/FiO2 value by about 50 and 70 mmHg for normo- and hypertensive pa-
tients, respectively. An equivalent intake of DRI drugs increases this ratio even
more, by 70 and 150 mmHg, while ARB administration decreases it by 140 and 30
mmHg. The opposite behavior of ARBs with respect to the other two antihyper-
tensive drugs comes from the fact that it provokes a substantial increase in AngII
concentration that is only partially balanced by a relative small increase of Ang1-7
level, given that ACE2 is downregulated in the SARS-CoV-2 infection.
Note that different ARB-type drugs such as valsartan and losartan are currently
tested in clinical trials in view of rescuing the RAS system in SARS-CoV-2 in-
fected patients with different severity [25, 26, 27]. Our model lets foresee a negative
outcome.
Finally, as shown in Table 5, the blood pressure is predicted to be essentially
constant upon administration to normotensive COVID-19 patients of the three
antihypertensive drugs analyzed here, while it drops by about 10-20 mmHg for
hypertensive patients.
(a)
Ct
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• Angiotensin receptor blockers (ARB) that block the binding of AngII to AT1R
and thus act in antagonism with AngII. Examples are candesartan, losartan
and valsartan.
• Direct renin inhibitors (DRI) that act on renin and thus inihibit the conver-
sion of AGT to AngI. Examples are aliskiren, enalkiren and remikiren.
We modeled the action of these three types of drugs by modifying the reaction
rates associated to their targets as:
cace  ! cace ⇥ (1   ACE-I)
cat1r  ! cat1r ⇥ (1   ARB)
cre  ! cre ⇥ (1   DRI) (13)
where  ACE-I,  ARB and  DRI are parameters describing the drug activity.
Modeling CoViD-19 infection
Since ACE2 is the entry point of SARS-CoV-2 [19], it is downregulated upon in-
fection, and this impacts substantially on the local and systemic RAS systems. In
order to model the downregulation e↵ect due to the virus, we modified the ACE2
rate with the function  CoV as:
cace2  ! cace2 ⇥ (1   CoV(Ct)) (14)
This function depends on the virus cycle threshold value Ct, which is inversely
related to the viral load [69].
Monitoring the acute respiratory distress syndrome and its severity
To model how the lungs of the infected patients evolve in response to the modulation
of the RAS system, we introduced a phenomenological relation to estimate the
PaO2/FiO2 ratio, defined as the ratio between the partial pressure of arterial
oxygen (PaO2) and the fraction of inspired oxygen. This quantity plays a key role
in the assessment of ARDS patients [34, 35]. The normal range of PaO2/FiO2
is between 400 and 500 mmHg. Mild and moderate ARDS are characterized by
PaO2/FiO2 values in the range [200–300] mmHg and [100-200] mmHg, respectively.
ARDS is severe for values below 100 mmHg.
We predicted the PaO2/FiO2 ratio as a function of the AngII and Ang1-7 con-
centrations:
PaO2/FiO2 = A0 +A1
✓
  [AngII]
[AngII]0
+
[Ang1-7]
[Ang1-7]0
◆
(15)
where A0 and A1 are two parameters that we identified from our model by com-
paring the baseline RAS with the same system in which ACE2 is knocked out. In
the former we fixed PaO2/FiO2= 450 mmHg and in the latter PaO2/FiO2= 50
mmHg.
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The mathematical model of the RAS system described in Eqs (1)-(11) is a system of
ordinary di↵erential equations (ODEs), which are linear except for the feedback loop of Eq.
(11). We collected from the literature the values of the equilibrium concentrations of all
proteins and peptides for both normotensive and hypertensive humans (Table 1), except
renin and MAS bound to Ang1-7. From these values, we fixed the parameters that appear in
the phenomenological relations (12) and (15) for DBP and PaO2/FiO2 (2).
We also got the values of the half-life of all proteins and peptides but MAS; we assumed the
latter to be equal to that of the other membrane receptors (Table 2). Moreover, we estimated
the value of reaction rate cre from [32, 33].
Using these concentration and parameter values, we solved the system of 9 ODEs (1)-(11)
at the stationary state to identify the unknown parameters and concentrations. However,
these equations have 12 unknowns: kagt,  0, cace, cace2, cangIV , cat1r, cat2r, cmas, cchy, cnep,
[RE] and [MAS-Ang1-7]. We had thus to assume three additional relations to be able to solve
the system. These are:
cmas = cat2r (16)
cchy = 0 (17)
cnep = 0 (18)
Since no quantitative data related to t e MAS receptor can be fou d in the literature, we
hypothesized the first relation assuming MAS and AT2R to be equally expressed and the a nity
of Ang1-7 for MAS to be similar to the a nity of AngII for AT2R [46]. Moreover, we assumed
cchy = 0 and cnep = 0, but carefully discussed the e↵ect of non-vanishing values in the
Discussion section.
Imposing these three additional relations, we solved the system of 9 ODEs (1)-(11) at the
stationary state. The values obtained for [RE] and [MAS-Ang1-7], kagt,  0, cace, cace2, cangIV ,
cat1r and cat2r for normotensive and hypertensive humans are given in Table 1.
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I posing the e three addi ional relations, we solved the system of 9 ODEs (1)-(11) at the
station ry state. The values obtained for [RE] and [MAS-Ang1-7], kagt,  0, cace, cace2, cangIV ,
cat1r a d cat2r for normotensive and hypertensive humans are given in Table 1.
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• Angiotensin receptor blockers (ARB) that block the binding of AngII to AT1R
and thus act in antagonism with AngII. Examples are candesartan, losartan
and valsartan.
• Direct renin inhibitors (DRI) that act on renin and thus inihibit the conver-
sion of AGT to AngI. Examples are aliskiren, enalkiren and remikiren.
We modeled the action of these three types of drugs by modifying the reaction
r tes associated to their targets as:
cace  ! cace ⇥ (1   ACE-I)
cat1r  ! cat1r ⇥ (1   ARB)
cre  ! cre ⇥ (1   DRI) (13)
where  ACE-I,  ARB and  DRI are parameters describing the drug activity.
Modeling CoViD-19 infection
Since ACE2 is the entry point of SARS-CoV-2 [19], it is do nregulated upon in-
fection, a d this impacts substantially o the local a d systemic RAS systems. In
order o model the downregulation e↵ect due to the virus, we modified the ACE2
rate with the function  CoV as:
cace2  ! cace2 ⇥ (1   CoV(Ct)) (14)
This function depends on the virus cycle threshold value Ct, which is inversely
related to the viral load [69].
Monitoring the acute respiratory distress syndrome and its severity
To model how the lungs of the infected patients evolve in response to the modulation
of the RAS syste , we introduced a phenomenological relation to estimate the
PaO2/FiO2 ratio, defined as the ratio between the partial pressure of arterial
oxygen (PaO2) and the fraction of inspired oxygen. This quantity plays a key role
in the assessment of ARDS patients [34, 35]. The normal range of PaO2/FiO2
is between 400 and 500 mmHg. Mild and moderate ARDS are characterized by
PaO2/FiO2 values in the range [200–300] mmHg and [100-200] mmHg, respectively.
ARDS is severe for values below 100 mmHg.
We predicted the PaO2/FiO2 ratio as a function of the AngII and Ang1-7 con-
centrations:
PaO2/FiO2 = A0 +A1
✓
  [AngII]
[AngII]0
+
[Ang1-7]
[Ang1-7]0
◆
(15)
where A0 and A1 are two parameters that we identified from our model by com-
paring the baseline RAS with the same system in which ACE2 is knocked out. In
the former we fixed PaO2/FiO2= 450 mmHg and in the latter PaO2/FiO2= 50
mmHg.
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Solving the RAS model
xx should this part not be in t Re ults section? With the paragraph of Philippe ? xx
The mathematical model of the RAS system described in Eqs (1)-(11) is a system of
ordinary di↵erential equations (ODEs), which are linear except for the feedback loop of Eq.
(11). We collected from the literature the values of the equilibrium concentrations of all
proteins and peptides for both normotensive and hypertensive humans (Table 1), except
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the phenomenological relations (12) and (15) for DBP and P O2/FiO2 (2).
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latter to be equal to that of the other membrane receptors (Table 2). Moreover, we estimated
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Using these concentration and parameter values, we solved the system of 9 ODEs (1)-(11)
at the stationary state to identify the unknown parameters and conce trations. However,
these equations have 12 unknowns: kagt,  0, cace, cace2, cangIV , cat1r, cat2r, cmas, cchy, cnep,
[RE] and [MAS-Ang1-7]. We h d thus to assume three addition l relations to be able to solve
the syst m. T se e:
cmas = cat2r (16)
cchy = 0 (17)
cnep = 0 (18)
Since no quantitative data related to the MAS receptor can be found in the literature, we
hypothesized the first relation assuming MAS and AT2R to be equally expressed and the a nity
of Ang1-7 for MAS to be similar to the a nity of AngII for AT2R [46]. Moreover, we assumed
cchy = 0 and cnep = 0, but carefully discussed the e↵ect of non-vanishing values in the
Discussion section.
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Figure 4 Impact of different RAS-blocking drugs in normotensive (blue) and hypertensive (red)
SARS-CoV-2 infected patients. Predicted PaO2/FiO2 value as a function of the cycle treshold
value Ct and (a) γACE−I , (b) γARB and (c) γDRI functi ns modeling the intake of the
corresponding drugs.
• Other RAS-targeting drugs. We tested other drugs that are currently in clinical
trials to restore the functional activity of the perturbed RAS system up n viral in-
fection. First, we modeled the administration of an exogenous supplemen of rhACE2
Pucci et al. Page 16 of 22
Drugs No Drugs ACE-I ARB DRI rhACE2 Ang1-7
Normotensive - Moderate Infection
[AngII]/[AngII]0 1.29 1.10 1.98 0.99 1.10 1.29
[Ang1-7]/[Ang1-7]0 0.15 0.13 0.23 0.11 0.68 0.84
PaO2/FiO2 (mmHg) 145 188 0 216 337 330
DBP (mmHg) 82 81 80 80 81 82
Hypertensive - Moderate Infection
[AngII]/[AngII]0 1.42 1.12 1.55 0.77 1.14 1.42
[Ang1-7]/[Ang1-7]0 0.16 0.13 0.18 0.09 0.70 0.43
PaO2/FiO2 (mmHg) 115 185 83 268 332 187
DBP (mmHg) 125 114 101 102 115 125
Table 5 Predicted effects on AngII and Ang1-7 levels, PaO2/FiO2 and DBP upon drug intake by
normotensive and hypertensive COVID-19 patients. The drug intake in modeled by
γACE−I , γARB , γDRI = 0.5, and moderate SARS-CoV-2 infection by γCoV = 27.6.
(GSK2586881) and its effect on the RAS system by modifying the cace2 coefficient
defined in Eq. (14). This coefficient already includes the function γCoV mimicking
the SARS-CoV-2 infection, and we added the new function γrhACE2 associated to
the effect of rhACE2 administration:
cace2 −→ cace2 × (1 + γrhACE2 − γCoV(Ct)) (22)
According to our model, we observe an increase of the PaO2/FiO2 value upon
intake of exogenous rhACE2, and thus a weakening of the disease severity, as shown
in Fig. 5 and Table 5. The increase of PaO2/FiO2 is of about 200 mmHg when
γrhACE2 varies in the interval [0-0.5]. We also observe a reduction of the AngII level
and an increase of the Ang1-7 level.
These predictions are in agreement with animal and in vitro studies [18, 22], where
rhACE2 administration has led to an improvement of the disease condition through
a double action. First, its binding to the spike protein of the virus prevents inter-
action with endogenous ACE2 and slows down the viral infection. Second, rhACE2
administration increases the ACE2 activity, thus causing a reduction of the AngII
level and an increase of the Ang1-7 level, which results in the protection of the lung
from severe failure.
However, clinical trials on COVID-19 patients [20], to which different doses of
rhACE2 (0.1 mg/kg, 0.2 mg/kg, 0.4 mg/kg and 0.8 mg/kg) were administered at
different time intervals (2, 4, and 18 h), are only partly in agreement with our
predictions and the above described data. On the one hand, a drop in [AngII]
and an increase in [Ang1-7] was found as expected, but on the other hand no
sustained increase in PaO2/FiO2 was observed compared with placebo. It has been
argued that the drug concentration was too low and not sustained enough, and that
continuous drug infusion could reach a more effective result [20]. More experimental
and clinical data are needed to further investigate the effect of rhACE2 on ARDS
and perturbed RAS upon SARS-CoV-2 infection.
Another way to boost the second RAS axis ACE2/Ang1-7/MAS, which is down-
regulated upon SARS-CoV-2 infection, is to administrate Ang1-7 peptides to the
patients so as to trigger anti-inflammatory and anti-fibrotic mechanisms. We mod-
eled this administration through the introduction of a parameter η in the dynamical
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equation (9) of [Ang1-7], to describe the endogenously Ang1-7 quantity that is added
to the normal baseline quantity. As shown in Fig 5.b and Table 5, our model predicts
a clear decrease of the disease severity, with an increase in PaO2/FiO2 between 70
and 140 mmHg for hypertensive and normotensive patients, respectively, upon ad-
ministration of η =25 fmol/(ml min) Ang1-7 in infusion, which amounts to almost
doubling the control values [Ang1-7]0. Note that the improvement is significantly
more pronounced in normotensive than in hypertensive patients for equal drug con-
centrations; to reach the same effect, the Ang1-7 concentration administrated to
hypertensive patients have to be slightly increased.
Our results thus predict quantitatively an improvement of ARDS severity in
COVID-19 patients, in agreement with the known anti-inflammation and anti-
fibrosis nature of Ang1-7. Without any specific fitting, they nicely agree with data
from animal studies. For example, the administration of infusions yielding a renal
increase of [Ang1-7] by a factor 2.5 to acid-injured rats suffering from acute ARDS
led to an increase in PaO2/FiO2 of about 70 mmHg [77]. However, while the res-
cue effect of PaO2/FiO2 increases linearly in our model, a plateau in the increase
was observed for the rats. This indicates that our model is too simple and that
PaO2/FiO2 is not a linear function of Ang1-7 concentration. This will be easily
corrected when more data will be available.
(a)
Ct
(b)
Monitoring the acute respiratory distress syndrome and its severity
To model how the lungs of the infected patients evolve in response to the modulation of the
RAS system, we introduced a phenomenological relation to estimate the PaO2/FiO2 ratio,
defined as the ratio between the partial pressure of arterial oxygen (PaO2) and the fraction of
inspired oxygen. This quantity plays a key role in the assessment of ARDS patients [34, 35].
The normal range of PaO2/FiO2 is between 400 and 500 mmHg. Mild and moderate ARDS
are characterized by PaO2/FiO2 values in the range [200–300] mmHg and [100-200] mmHg,
respectively. ARDS is severe for values below 100 mmHg.
We predicted the PaO2/FiO2 ratio as a function of the AngII and Ang1-7 concentrations:
PaO2/FiO2 = A0 +A1
✓
  [AngII]
[AngII]0
+
[Ang1-7]
[Ang1-7]0
◆
(15)
where A0 and A1 are two parameters that we identified from our model by comparing the
baseline RAS with the same system in which ACE2 is knocked out. In the former we fixed
PaO2/FiO2= 450 mmHg and in the latter PaO2/FiO2= 50 mmHg.
Solving the RAS model
xx should this part not be in the Results section? With the paragraph of Philippe ? xx
The mathematical model of the RAS system described in Eqs (1)-(11) is a system of
ordinary di↵erential equations (ODEs), which are linear except for the feedback loop of Eq.
(11). We collected from the literature the values of the equilibrium concentrations of all
proteins and peptides for both normotensive and hypertensive humans (Table 1), except
renin and MAS bound to Ang1-7. From these values, we fixed the parameters that appear in
the phenomenological relations (12) and (15) for DBP and PaO2/FiO2 (2).
We also got the values of the half-life of all proteins and peptides but MAS; we assumed the
latter to be equal to that of the other membrane receptors (Table 2). Moreover, we estimated
the value of reaction rate cre from [32, 33].
Using these concentration and parameter values, we solved the system of 9 ODEs (1)-(11)
at the stationary state to identify the unknown parameters and concentrations. However,
these equations have 12 unknowns: kagt,  0, cace, cace2, cangIV , cat1r, cat2r, cmas, cchy, cnep,
[RE] and [MAS-Ang1-7]. We had thus to assume three additional relations to be able to solve
the system. These are:
cmas = cat2r (16)
cchy = 0 (17)
cnep = 0 (18)
Since no quantitative data related to the MAS receptor can be found in the literature, we
hypothesized the first relation assuming MAS and AT2R to be equally expressed and the a nity
of Ang1-7 for MAS to be similar to the a nity of AngII for AT2R [46]. Moreover, we assumed
cchy = 0 and cnep = 0, but carefully discussed the e↵ect of non-vanishing values in the
Discussion section.
Imposing these three additional relations, we solved the system of 9 ODEs (1)-(11) at the
stationary state. The values obtained for [RE] and [MAS-Ang1-7], kagt,  0, cace, cace2, cangIV ,
cat1r and cat2r for normotensive and hypertensive humans are given in Table 1.
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rhACE2 (GSK2586881). We modeled its e↵ect on the RAS system by odifying
the cace2 coe cient defined in Eq. (14) which already mimics the SARS-CoV-2
infection, as:
cace2  ! cace2 ⇥ (1 +  rhACE2    CoV(Ct)) (20)
We thus introduc d a ew gamma func io  rhACE2 associated to the e↵ect of
rhACE2 administration.
The predictions of our model are shown in Fig. 5 and Table 5. We observe an
increase of the PaO2/FiO2 value upon intake of exogenous rhACE2, and thus a
weakening of dis ase severity. The increase of PaO2/FiO2 is of about 200
mmHg when  rhACE2 varies in the interval [0-0.5]. We also observe a reduction of
the AngII level and an increase of the Ang1-7 level.
These predictions are in agreement with animal and in vitro studies [18, 27],
where rhACE2 administration h s led to an improvement of the disease condition
through a double action. First, its binding to the S-protein of the virus xx S or S1 ?
xx prevents interaction with endogenous ACE2 and slows down the viral infection.
Second, rhACE2 administration increases the ACE2 activity, thus causing a reduction
of the AngII level and an increase of the Ang1-7 level, which results in the protection
of the lung from severe failure.
However, our predictions and the data described above do not agree with clinical
trials clinical data [2 ] regarding the administration of rhACE2 at di↵ere t doses
(0.1 mg/kg, 0.2 mg/kg, 0.4 mg/kg and 0.8 mg/kg) and intervals (2, 4, and 18 h)
to CoViD patients are less positive. A drop in [ANGII] and an increase in [ANG1-7]
was found, similar to what we found, but no sustained increase of PaO2/FiO2 was
observed for these patients compared with placebo, in contrast with what happens
from animal model, . However there is the possibility that drug concentrations
were not enough substained and that maybe only trough its continuous infusions
could reach a more e↵ective result [20]. More experimental data are needed to
further investigate e↵ect of rhACE2 on ARDS and preturbed RAS system due to
the SARS-CoV-2 infection.
Another way to maintain an high level of the ACE2/Ang1-7/MasR negative
counter-regulation in CoViD is to administrate the Ang1-7 peptide to trigger anti-
inflammatory and antifibrotic mechanisms. In our computation we model this ad-
ministration introducing the parameter ⌘ describing the endogenously Ang1-7 quan-
tity that is added to the normal baseline quantity. We can see the results of the
computation in Fig 5.b and in Table XXX where a clear improvement of the dis-
ease severity is observed with an increase PaO2/FiO2 between 70 and 140 mmHg
for hypertensive and normotensve patients respectivley and for administration in
infusion of 25 fmol/ml that means almost doubling the control values Ang1-70 Note
that the improvement is significantly more pronounced in normotensive patients
than in hypertensive ones for equal drug concentrations and to reach the same ef-
fects the Ang1-7 concentration administrated to hypertensive patients have to be
slightly increased.
In agreement with clinical data on human ARDS and with the anti-inflammation
and anti-fibrosis nature of Ang1-7, our results predict quantitatively an improvenent
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Figure 5 Impact on the PaO2/FiO2 value of the administr tion of rhACE2 and Ang1-7 in
normotensive (blue) and hypertensive (red) SARS-C V-2 inf cted patient . (a) Predicted
PaO2/FiO2 values as a function of Ct and γrhACE2 (b) Predic ed PaO2/FiO2 valu s as
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4 Conclusion a d Perspectives
The spike protein of SARS-CoV-2 interferes with the RAS system, as it binds to one
of its key elements, the ACE2 r ceptor. Despite some progress in the last few months
in understanding the COVID-perturbed RAS system and h w ts functionality ca
be restored, this issue remains basically open and is urgently waiting to be elucidated
in view of tackling the COVID-19 pandemic more fficiently.
We presented a simple computational approach for model ng the volution of the
RAS system upon SARS-CoV-2 infection. Inspired by some existing RAS models
[41, 42, 52, 59], we started by identifying the unknown production and reaction rate
parameters of the model on the basis of the measured half-lives and concentrations
of angiotensin peptides and their receptors at equilibrium in normotensive and
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hypertensive individuals, which we manually collected from the literature. As a first
test, we compared the predictions of our model with experimental data regarding the
effect of RAS-blocking drug administration on Ang peptide concentrations and blood
pressure. We found our model to correctly reproduce the data at a quantitative
level without further parameter fitting. We then modeled the effect of SARS-CoV-2
on the RAS system through the downregulation of ACE2 concentration, which we
related to the SARS-CoV-2 viral load.
As a central point of our paper, we investigated the effect on COVID-19 patients
of a series of drugs that target the RAS system. Regarding antihypertensive drugs,
we found that ACE-I and DRI tend to improve the patients’ conditions while ARB
drugs worsen them. Clinical data tend to support our ACE-I predictions, while for
DRI and ARB, there is either no or partially conflicting data. We also studied the
effect of the infusion of rhACE2 and Ang1-7, which are treatments that are currently
in clinical trials on COVID-19 patients. We also found in this case an improvement
of the clinical outcome, in agreement with a series of experimental data on animal
models.
We would like to emphasize that, despite its simplicity, our model reaches a
very good accuracy in reproducing the known clinical and experimental data on
the perturbed RAS system. What is more, the predictions of our model regarding
COVID-19 severity upon drug administration are actually blind predictions, since
no parameters related to these quantities have been fitted.
Many questions remain regarding the understanding of RAS perturbation in
COVID-19 patients. First, it is urgent to have more data about angiotensin pep-
tide concentrations upon SARS-CoV-2 infection, since the data described in the
literature vary too much and are sometimes even conflicting, and thus prevent the
derivation of insightful conclusions. Even in healthy individuals, the magnitude of
angiotensin peptide levels can vary substantially due to their low circulating con-
centrations, the experimental techniques used to quantify these, and interpersonal
differences among patients.
A last point needs to be discussed. We chose not to consider two enzymes that
are nevertheless active in the RAS system, chymase and neprilysin, through the
cancellation of their reaction rates (Eqs (18)-(19)). CHY is an enzyme expressed in
mast cells present in interstitial lung connective tissues, and cleaves AngI to form
AngII. The addition of this enzymatic reaction in the model does not really influence
the predictions as it can basically be viewed as a reparametrization of ACE activity
and of ACE-I action; moreover, this enzyme is only poorly expressed in the lungs
of healthy individuals. It could nevertheless be interesting to add this enzymatic
reaction yielding ACE-independent synthesis of AngII which, even though debated,
has been suggested to be upregulated in case of long-term ACE-I administration
[78] and to explain why ACE-I fails to inhibit AngII formation after some time
[78, 79].
The second enzyme of which we overlooked the activity is NEP, which cleaves
AngI to form Ang1-7. It is expressed in a wide range of tissues and is particu-
larly abundant in kidney. This enzyme can impact on COVID-19 severity, since it
is connected to the Ang1-7 level and thus influences the counterregulatory RAS
axis. However, NEP’s role is far from clear and contrasting results are found in the
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literature. Experimental data from animal tests on rats affected by ARDS suggest
that NEP is severely downregulated in both plasma and lung tissues [80]. Note that
this enzyme also cleaves natriuretic peptides which have an anti-inflammatory and
anti-fibrotic effect [81]. Therefore, NEP-inhibiting drugs have been suggested to treat
SARS-CoV-2 infected patients in association with ARB drugs [82].
Our future objective is to complexify our model by explicitly considering the com-
munication between local and systemic RAS systems [33, 34] and by including the
interaction of RAS with the immune system [83]. This model extension is necessary
in view of understanding more quantitatively the dysregulation of the RAS system
upon several kinds of perturbations among which SARS-CoV-2 infection.
In summary, our model and its predictions constitute a valuable framework for in
silico testing of hypotheses about the COVID-19 pathogenic mechanisms and the
effect of drugs aiming to restore RAS functionality. It also opens a broader discus-
sion on the role played by the full RAS system in COVID-19, which is currently
overlooked as the focus is on the ACE2 enzyme which, although very important as
directly targeted by the virus, constitutes only one part of the system.
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